Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 627

1.

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.

Oshima M, Jun M, Ohkuma T, Toyama T, Wada T, Cooper ME, Hadjadj S, Hamet P, Harrap S, Mancia G, Marre M, Williams B, Chalmers J, Woodward M, Perkovic V; ADVANCE Collaborative Group.

Diabetologia. 2019 Jul 13. doi: 10.1007/s00125-019-4948-4. [Epub ahead of print]

PMID:
31302707
2.

Feeding garden birds.

Cooper JE, Cooper ME, King S.

Vet Rec. 2019 Jul 13;185(2):56. doi: 10.1136/vr.l4593. No abstract available.

PMID:
31296718
3.

Diagnosis and Management of Periprosthetic Joint Infection After Shoulder Arthroplasty.

Cooper ME, Trivedi NN, Sivasundaram L, Karns MR, Voos JE, Gillespie RJ.

JBJS Rev. 2019 Jul 9. doi: 10.2106/JBJS.RVW.18.00152. [Epub ahead of print] No abstract available.

PMID:
31291202
4.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.

Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A.

Am J Kidney Dis. 2019 Jun 26. pii: S0272-6386(19)30735-8. doi: 10.1053/j.ajkd.2019.03.432. [Epub ahead of print] No abstract available.

PMID:
31255334
5.

Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse.

Jha JC, Dai A, Holterman CE, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm KAM.

Diabetologia. 2019 Jun 20. doi: 10.1007/s00125-019-4924-z. [Epub ahead of print]

PMID:
31222503
6.

Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes.

Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, Zoungas S, Perkovic V, Woodward M; ADVANCE Collaborative Group.

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):862-872. doi: 10.2215/CJN.13391118. Epub 2019 Jun 3.

PMID:
31160317
7.

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.

Warren AM, Knudsen ST, Cooper ME.

Expert Opin Ther Targets. 2019 Jul;23(7):579-591. doi: 10.1080/14728222.2019.1624721. Epub 2019 Jun 3.

PMID:
31154867
8.

Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.

Selvin E, Wang D, McEvoy JW, Juraschek SP, Lazo M, Hamet P, Cooper ME, Marre M, Williams B, Harrap S, Chalmers J, Woodward M.

Diabetes Obes Metab. 2019 Aug;21(8):2017-2023. doi: 10.1111/dom.13755. Epub 2019 May 29.

PMID:
31050156
9.

The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.

Mohan V, Cooper ME, Matthews DR, Khunti K.

Diabetes Ther. 2019 Mar;10(Suppl 1):1-13. doi: 10.1007/s13300-019-0573-y. Epub 2019 Feb 13. Review.

10.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
11.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
12.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
13.

Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.

Ohkuma T, Jun M, Rodgers A, Cooper ME, Glasziou P, Hamet P, Harrap S, Mancia G, Marre M, Neal B, Perkovic V, Poulter N, Williams B, Zoungas S, Chalmers J, Woodward M; ADVANCE Collaborative Group.

Hypertension. 2019 Jan;73(1):84-91. doi: 10.1161/HYPERTENSIONAHA.118.12060.

14.

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Cooper ME, Perkovic V, Groop PH, Hocher B, Hehnke U, Meinicke T, Koitka-Weber A, van der Walt S, von Eynatten M.

J Hypertens. 2019 Jun;37(6):1294-1300. doi: 10.1097/HJH.0000000000002032.

PMID:
30540657
15.

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.

Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, Huet O, Seeber RM, Abhayawardana R, Johnstone EK, Golledge J, Wang Y, Jandeleit-Dahm KA, Cooper ME, Pfleger KD, Thomas MC.

J Clin Invest. 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10.

16.

Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy.

Chai Z, Wu T, Dai A, Huynh P, Koentgen F, Krippner G, Ren S, Cooper ME.

Diabetes. 2019 Feb;68(2):395-408. doi: 10.2337/db18-0712. Epub 2018 Nov 13.

PMID:
30425061
17.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

18.

Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis.

Brennan EP, Mohan M, McClelland A, de Gaetano M, Tikellis C, Marai M, Crean D, Dai A, Beuscart O, Derouiche S, Gray SP, Pickering R, Tan SM, Godson-Treacy M, Sheehan S, Dowdall JF, Barry M, Belton O, Ali-Shah ST, Guiry PJ, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2018 Dec;67(12):2657-2667. doi: 10.2337/db17-1317. Epub 2018 Sep 13.

19.

Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial.

Thomas MC, Woodward M, Li Q, Pickering R, Tikellis C, Poulter N, Cooper ME, Marre M, Zoungas S, Chalmers J; ADVANCE Collaborative Group.

J Am Heart Assoc. 2018 Jun 30;7(13). pii: e008226. doi: 10.1161/JAHA.117.008226.

20.

Cardiovascular Disease and Diabetic Kidney Disease.

Maqbool M, Cooper ME, Jandeleit-Dahm KAM.

Semin Nephrol. 2018 May;38(3):217-232. doi: 10.1016/j.semnephrol.2018.02.003. Review.

PMID:
29753399
21.

Pathophysiological Links Between Diabetes and Blood Pressure.

Libianto R, Batu D, MacIsaac RJ, Cooper ME, Ekinci EI.

Can J Cardiol. 2018 May;34(5):585-594. doi: 10.1016/j.cjca.2018.01.010. Epub 2018 Jan 31. Review.

PMID:
29731021
22.

Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture.

Cooper ME, El-Osta A, Allen TJ, Watson AMD, Thomas MC, Jandeleit-Dahm KAM.

Diabetes. 2018 May;67(5):785-790. doi: 10.2337/dbi18-0010. Review.

23.

New Glucose-Lowering Agents for Diabetic Kidney Disease.

de Vos LC, Hettige TS, Cooper ME.

Adv Chronic Kidney Dis. 2018 Mar;25(2):149-157. doi: 10.1053/j.ackd.2018.01.002. Review.

PMID:
29580579
24.

Ultrasound Combined with Microbubbles Enhances the Effects of Methylprednisolone in Lipopolysaccharide-Induced Human Mesangial Cells.

Sun PF, Tian T, Chen LN, Fu RG, Xu SS, Ai H, Wang B, Zhang J, Si RY, Chai Z, Cooper ME, Ren ST.

J Pharmacol Exp Ther. 2018 Jun;365(3):476-484. doi: 10.1124/jpet.117.246223. Epub 2018 Mar 16.

PMID:
29549156
25.

Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets.

Ju L, McFadyen JD, Al-Daher S, Alwis I, Chen Y, Tønnesen LL, Maiocchi S, Coulter B, Calkin AC, Felner EI, Cohen N, Yuan Y, Schoenwaelder SM, Cooper ME, Zhu C, Jackson SP.

Nat Commun. 2018 Mar 14;9(1):1087. doi: 10.1038/s41467-018-03430-6.

26.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA® investigators.

Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3.

27.

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

Brennan EP, Mohan M, McClelland A, Tikellis C, Ziemann M, Kaspi A, Gray SP, Pickering R, Tan SM, Ali-Shah ST, Guiry PJ, El-Osta A, Jandeleit-Dahm K, Cooper ME, Godson C, Kantharidis P.

J Am Soc Nephrol. 2018 May;29(5):1437-1448. doi: 10.1681/ASN.2017101112. Epub 2018 Feb 28.

28.

RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis.

Hagiwara S, Sourris K, Ziemann M, Tieqiao W, Mohan M, McClelland AD, Brennan E, Forbes J, Coughlan M, Harcourt B, Penfold S, Wang B, Higgins G, Pickering R, El-Osta A, Thomas MC, Cooper ME, Kantharidis P.

Diabetes. 2018 May;67(5):960-973. doi: 10.2337/db17-0538. Epub 2018 Feb 15.

29.

Heterogeneity of Reporting Outcomes in the Spine Surgery Literature.

Cooper ME, Torre-Healy LA, Alentado VJ, Cho S, Steinmetz MP, Benzel EC, Mroz TE.

Clin Spine Surg. 2018 May;31(4):E221-E229. doi: 10.1097/BSD.0000000000000578.

PMID:
29315117
30.

Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1).

Li J, Huynh P, Dai A, Wu T, Tu Y, Chow B, Kiriazis H, Du XJ, Bach LA, Wilkinson-Berka JL, Biros E, Walker P, Nataatmadja M, West M, Golledge J, Allen TJ, Cooper ME, Chai Z.

Diabetes. 2018 Apr;67(4):755-768. doi: 10.2337/db17-0134. Epub 2018 Jan 8.

31.

Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, Hamet P, Mancia G, Colagiuri S, Williams B, Grobbee DE, DeVries JH; ADVANCE Collaborative Group.

Diabetologia. 2018 Apr;61(4):780-789. doi: 10.1007/s00125-017-4539-1. Epub 2018 Jan 8.

32.

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.

d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME.

Diabetes Res Clin Pract. 2018 Feb;136:23-31. doi: 10.1016/j.diabres.2017.11.023. Epub 2017 Dec 2. Review.

PMID:
29196150
33.

Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2.

Moran CS, Biros E, Krishna SM, Wang Y, Tikellis C, Morton SK, Moxon JV, Cooper ME, Norman PE, Burrell LM, Thomas MC, Golledge J.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2195-2203. doi: 10.1161/ATVBAHA.117.310129. Epub 2017 Sep 21.

PMID:
28935757
34.

Diabetic kidney disease: as easy as aPC?

McFadyen JD, Cooper ME.

Blood. 2017 Sep 21;130(12):1390-1391. doi: 10.1182/blood-2017-08-798314. No abstract available.

35.

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS.

Kidney Int. 2018 Jan;93(1):231-244. doi: 10.1016/j.kint.2017.06.017. Epub 2017 Aug 30.

PMID:
28860019
36.

NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.

Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K.

Diabetes. 2017 Oct;66(10):2691-2703. doi: 10.2337/db16-1585. Epub 2017 Jul 26.

37.

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.

Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, Hamet P, Mancia G, Williams B, Welsh P, Sattar N, Shaw JE, Rahimi K, Chalmers J; ADVANCE Collaborative Group.

Diabetes Care. 2017 Sep;40(9):1203-1209. doi: 10.2337/dc17-0509. Epub 2017 Jul 6.

38.

Clinical Science: showcasing the breadth of the journal.

Cooper ME, Touyz RM.

Clin Sci (Lond). 2017 Jun 30;131(14):1559. doi: 10.1042/CS20171099. Print 2017 Jul 15.

PMID:
28667058
39.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.

40.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
41.

Dental Decay Phenotype in Nonsyndromic Orofacial Clefting.

Howe BJ, Cooper ME, Wehby GL, Resick JM, Nidey NL, Valencia-Ramirez LC, Lopez-Palacio AM, Rivera D, Vieira AR, Weinberg SM, Marazita ML, Moreno Uribe LM.

J Dent Res. 2017 Sep;96(10):1106-1114. doi: 10.1177/0022034517709961. Epub 2017 May 23.

42.

Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.

Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, Basu D, Heywood S, Kammoun HL, Flynn M, Whillas A, Hanssen NM, Febbraio MA, Westein E, Fisher EA, Chin-Dusting J, Cooper ME, Berger JS, Goldberg IJ, Nagareddy PR, Murphy AJ.

J Clin Invest. 2017 Jun 1;127(6):2133-2147. doi: 10.1172/JCI92450. Epub 2017 May 15.

43.

Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis.

Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O, Derouiche S, Gray S, Pickering R, Tikellis C, de Gaetano M, Barry M, Belton O, Ali-Shah ST, Guiry P, Jandeleit-Dahm KAM, Cooper ME, Godson C, Kantharidis P.

Diabetes. 2017 Aug;66(8):2266-2277. doi: 10.2337/db16-1405. Epub 2017 May 9.

44.

Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.

Gray SP, Jha JC, Kennedy K, van Bommel E, Chew P, Szyndralewiez C, Touyz RM, Schmidt HHHW, Cooper ME, Jandeleit-Dahm KAM.

Diabetologia. 2017 May;60(5):927-937. doi: 10.1007/s00125-017-4215-5. Epub 2017 Feb 3.

PMID:
28160092
45.

Hypoglycaemia in patients with diabetes mellitus and renal impairment.

Hettige TS, Cooper ME.

Diab Vasc Dis Res. 2017 Mar;14(2):166-168. doi: 10.1177/1479164116683082. Epub 2017 Jan 27. No abstract available.

PMID:
28128009
46.

Genetics of Diabetic Kidney Disease-From the Worst of Nightmares to the Light of Dawn?

Ma RC, Cooper ME.

J Am Soc Nephrol. 2017 Feb;28(2):389-393. doi: 10.1681/ASN.2016091028. Epub 2016 Nov 23. No abstract available.

47.

Set7 mediated interactions regulate transcriptional networks in embryonic stem cells.

Tuano NK, Okabe J, Ziemann M, Cooper ME, El-Osta A.

Nucleic Acids Res. 2016 Nov 2;44(19):9206-9217. Epub 2016 Jul 20.

48.

Protective Effect of Inflammasome Activation by Hydrogen Peroxide in a Mouse Model of Septic Shock.

Huet O, Pickering RJ, Tikellis C, Latouche C, Long F, Kingwell B, Dickinson B, Chang CJ, Masters S, Mackay F, Cooper ME, de Haan JB.

Crit Care Med. 2017 Feb;45(2):e184-e194. doi: 10.1097/CCM.0000000000002070.

49.

A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation.

Marshall JD, Heeke DS, Rao E, Maynard SK, Hornigold D, McCrae C, Fraser N, Tovchigrechko A, Yu L, Williams N, King S, Cooper ME, Hajjar AM, Woo JC.

PLoS One. 2016 Oct 13;11(10):e0164632. doi: 10.1371/journal.pone.0164632. eCollection 2016.

50.

Treatment of Distal Femur Nonunion Following Initial Fixation with a Lateral Locking Plate.

Ebraheim NA, Buchanan GS, Liu X, Cooper ME, Peters N, Hessey JA, Liu J.

Orthop Surg. 2016 Aug;8(3):323-30. doi: 10.1111/os.12257.

PMID:
27627715

Supplemental Content

Loading ...
Support Center